Cancer immunotherapy strategies that target the cGAS-STING pathway

Zhuoying Tian; Yue Zeng; Yurong Peng; Junqi Liu; Fang Wu

doi:10.3389/fimmu.2022.996663

Cancer immunotherapy strategies that target the cGAS-STING pathway

Front Immunol. 2022 Oct 24:13:996663. doi: 10.3389/fimmu.2022.996663. eCollection 2022.

Authors

Zhuoying Tian^{1

2}, Yue Zeng¹, Yurong Peng¹, Junqi Liu¹, Fang Wu^{1

3

4

5}

Affiliations

¹ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
² Xiangya School of Medicine, Central South University, Changsha, China.
³ Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Changsha, China.
⁴ Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
⁵ Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, China.

Abstract

Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges.

Keywords: STING; cGAS; cancer-immunity cycle; immunotherapy; tumor.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

DNA
Humans
Immunotherapy
Membrane Proteins* / genetics
Neoplasms*
Nucleotidyltransferases / metabolism

Substances

DNA
Membrane Proteins
Nucleotidyltransferases
STING1 protein, human